ENHERTU® Demonstrates Efficacy in HER2 Positive Metastatic Breast Cancer Patients
Friday, 13 September 2024, 07:01
ENHERTU® Shows Promise in Treating HER2 Positive Metastatic Breast Cancer
Recent studies have highlighted the effectiveness of ENHERTU® in patients with HER2 positive metastatic breast cancer. Specifically, clinical trials reveal significant activity against this challenging cancer type.
Key Findings
- Substantial Clinical Activity: Patients receiving ENHERTU® displayed a marked reduction in tumor progression.
- Incidence of ILD: In patients treated with ENHERTU® at 5.4 mg/kg, interstitial lung disease (ILD) occurred in 12% of cases.
- Median Time to First Onset: The average onset for ILD was 5.5 months, indicating a need for monitoring.
Implications for Future Treatment Protocols
This data stresses the importance of vigilance when administering ENHERTU® for metastatic breast cancer and offers hope for improved patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.